Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942


News SummaryMost relevantAll newsSector newsTweets 


share with twitter share with LinkedIn share with facebook
share via e-mail
04/23/2012 | 07:17pm CEST
ABLYNX ANNOUNCES WARRANT EXERCISE GHENT, Belgium, 23 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that an additional 5,000 common shares have been issued by the Company in exchange for €7,000 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 43,709,895 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact: Ablynx:

Dr Edwin Moses

Chairman and CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: [email protected]

Marieke Vermeersch Investor Relations Manager t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: [email protected]


Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t: +44 207 920 2330

e: [email protected]

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward - looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the
Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABLYNX
06/27 ABLYNX : 27/06/2017 ablynx achieves second milestone in immuno-oncology collabor..
06/27 ABLYNX : Achieves second milestone in immuno-oncology collaboration with merck &..
06/26 ABLYNX : 26/06/2017 ablynx initiates a single and multiple dose phase i study of..
06/26 ABLYNX : Initiates a single and multiple dose phase i study of caplacizumab in h..
06/26 ABLYNX : Initiates a single and multiple dose phase i study of caplacizumab in h..
06/16 ABLYNX : 16/06/2017 publication in accordance with article 14 of the belgian law..
06/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
06/14 ABLYNX : 14/06/2017 ablynx to present additional data for its anti-il-6r nanobod..
06/14 ABLYNX : To present additional data for its anti-il-6r nanobody, vobarilizumab, ..
06/13 ABLYNX : Appoints markus ewert as chief business officer
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/27 Ablynx earns ?2.5M milestone from collaboration partner Merck
06/15 Therapy Focus - Lupus Hopes Build But Data Remain On The Distant Horizon
06/06 Ablynx (ABLYF) Presents At Jefferies 2017 Global Healthcare Conference - Slid..
05/22 Novel Nanobody to start clinical development in osteoarthritis - Ablynx to re..
05/11 Ablynx NV reports Q1 results
Financials (€)
Sales 2017 50,4 M
EBIT 2017 -60,2 M
Net income 2017 -71,4 M
Finance 2017 26,2 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 13,6x
EV / Sales 2018 12,4x
Capitalization 709 M
More Financials
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 16,3 €
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP27.49%16 010
CELLTRION, INC.--.--%12 252
ALKERMES PLC4.89%8 957
More Results